Source: DGNews  |  Posted 8 years ago

By Mary Beth Nierengarten

MINNEAPOLIS, MN -- September 26, 2003 -- Risedronate reduces vertebral fractures in men with primary and secondary osteoporosis after 1 year of treatment, according to a study presented here September 20th at the 25th Annual Meeting of the American Society for Bone and Mineral Research.

Although the efficacy of risedronate to reduce the risk of vertebral and non-vertebral fractures in postmenopausal women is well known, it has not been as studied extensively in men.

The incidence of hip fractures in men as well as women is on the increase, and projected to exceed 1.1 million by 2025. To determine the efficacy of risedronate in men with osteoporosis, Dr. J. D. Ringe, Hospital Leverkusen, Germany, conducted an open label, prospective clinical trial of 280 men with low lumber spine (LS) bone mineral density (BMD) (less than